Vertex Spots Potential Bargain Of $60m Entry Into Complement Regulation

Cash-Strapped Catalyst Bio Forced Into Quick Sale

 
• By Andrew McConaghie

Vertex has acquired the full assets to a promising protease-based drug platform from Catalyst, broadening its R&D base once again.

Vertex Mobile
Rights to the assets were handed back by Biogen in March, and have now been acquired in full by Vertex. • Source: Shutterstock

More from Deals

More from Business